These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

969 related articles for article (PubMed ID: 17483366)

  • 1. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
    Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells.
    Bosch JJ; Iheagwara UK; Reid S; Srivastava MK; Wolf J; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2010 Jan; 59(1):103-12. PubMed ID: 19557412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
    Smythe JA; Fink PD; Logan GJ; Lees J; Rowe PB; Alexander IE
    J Immunol; 1999 Sep; 163(6):3239-49. PubMed ID: 10477593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.
    Abdel-Wahab ZA; Osanto S; Darrow TL; Barber JR; Vervaert CE; Gangavalli R; McCallister TJ; Seigler HF
    Cancer Gene Ther; 1994 Sep; 1(3):171-9. PubMed ID: 7621248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
    Ogasawara M; Rosenberg SA
    Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
    Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
    Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
    Radosevich M; Jager M; Ono SJ
    Exp Mol Pathol; 2007 Feb; 82(1):68-76. PubMed ID: 16650406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
    Röhn TA; Reitz A; Paschen A; Nguyen XD; Schadendorf D; Vogt AB; Kropshofer H
    Cancer Res; 2005 Nov; 65(21):10068-78. PubMed ID: 16267033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid expansion of tumor-reactive cells from HLA-matched siblings for adoptive immunotherapy of melanoma.
    Gottlieb DJ; Micklethwaite K; Bradstock KF; Li YC
    Cytotherapy; 2007; 9(2):133-43. PubMed ID: 17453965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
    Zeng G
    J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients.
    Maat W; van der Slik AR; Verhoeven DH; Alizadeh BZ; Ly LV; Verduijn W; Luyten GP; Mulder A; van Hall T; Koning F; Jager MJ; van Bergen J
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2888-95. PubMed ID: 19234348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma.
    Guerry D; Alexander MA; Elder DE; Herlyn MF
    J Immunol; 1987 Jul; 139(1):305-12. PubMed ID: 3108402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.